NOTICE DURING COVID-19

THE HEALTH AND SAFETY OF OUR CUSTOMERS AND PATIENTS ARE ALWAYS OUR PRIORITY

With the current global pandemic, Sanofi and Regeneron Pharmaceuticals, Inc. would like to reinforce our commitment to you and your patients. As COVID-19 remains a serious concern, we are continuing to closely monitor the latest guidelines from the Centers for Disease Control and Prevention (CDC) to ensure that we have the most up-to-date health and safety guidance in place.

YOUR PATIENTS MAY HAVE QUESTIONS

We understand that your patients may contact you with more questions than usual regarding their treatment. We would like to take this opportunity to remind you of important information regarding DUPIXENT and resources available to you and your patients.

DUPIXENT IS A DUAL
INHIBITOR OF IL-4 AND IL-13 SIGNALING AND IS NOT AN IMMUNOSUPPRESSANT1,a

aThe mechanism of action of dupilumab in asthma has not been definitively established

DUPIXENT MyWay® CONTINUES TO HELP SUPPORT YOU AND YOUR PATIENTS BY PROVIDING NURSING, COVERAGE, AND ACCESS SUPPORT.

At this time, we have temporarily expanded our patient support offerings for DUPIXENT



For more information about financial assistance options that may be available to help your patients, contact DUPIXENT MyWay at 1-844-DUPIXENT (1-844-387-4936)

DUPIXENT offers the choice of at-home administration

Patients can self-administer DUPIXENT at home after being trained in subcutaneous injection technique by a healthcare professional.

Patients and caregivers have access to supplemental injection training without leaving home through the DUPIXENT MyWay support program. There are 2 options available:

  • Virtual injection training with a Nurse Educator
  • Training by phone with a Nurse Educator

In children 12 years of age and older, it is recommended that DUPIXENT be administered by or under supervision of an adult. In children younger than 12 years of age, DUPIXENT should be given by a caregiver.

Please note that in-person supplemental injection training has been temporarily suspended.

Additional injection training resources are also available online at DUPIXENT.COM:

WE CONTINUE TO OFFER SUPPORT TO YOUR PATIENTS

DUPIXENT MyWay is available to help provide nursing, coverage, and access support. You and your patients can contact DUPIXENT MyWay at 1-844-DUPIXENT (1-844-387-4936).

CoverMyMeds SpecialtyPlus Support is available for DUPIXENT!

CoverMyMeds provides additional prior authorization process related support for DUPIXENT.

Live support is available at

Up-to-date Clinical Information Concerning COVID-19 is Available Online From
Professional Medical Associations

Please refer to the websites of:

  • American Academy of Allergy, Asthma & Immunology (AAAAI)
  • American Academy of Dermatology (AAD)
  • American College of Allergy, Asthma, and Immunology (ACAAI)
  • Global Initiative for Asthma (GINA)

FINALLY, OUR THOUGHTS ARE WITH THOSE AFFECTED BY COVID-19

We will continue to closely monitor the situation, which has affected so many across the globe, and to evaluate our current support offerings. We hope that you and your loved ones remain safe and healthy.